Natural products and Pharma 2011: Strategic changes spur new opportunities

被引：97
作者：
Carter, Guy T. [1 ]
机构：
[1] Carter Bernan Consulting, New City, NY 10956 USA
来源：
NATURAL PRODUCT REPORTS | 2011年 / 28卷 / 11期
关键词：
PROTEIN-PROTEIN INTERACTIONS; DRUG DISCOVERY; POLYKETIDE SYNTHASE; INHIBITORS; PARADIGM;
D O I：
10.1039/c1np00033k
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although natural products have been marginalized by major pharmaceutical companies over the last 20-30 years, the changing landscape of drug discovery now favors a greatly enhanced role for Nature's privileged structures. Screening for drug leads in phenotypic screens provides the best opportunity to realize the value of natural products. Advances in total synthesis, especially function-oriented syntheses and biosynthetic technologies offer new avenues for the medicinal chemical optimization of biologically active secondary metabolites. Genomic research has given new insights into biosynthetic processes as well as providing evidence that a wealth of unrealized biosynthetic potential remains to be explored. As Pharma strives to develop innovative and highly effective new drugs, natural products will be increasingly valued as sources of novel leads whose further development will be expedited by emerging technologies.
引用
收藏
页码：1783 / 1789
页数：7
相关论文
共 32 条
  • [11] Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
    Hamann, PR
    Hinman, LM
    Hollander, I
    Beyer, CF
    Lindh, D
    Holcomb, R
    Hallett, W
    Tsou, HR
    Upeslacis, J
    Shochat, D
    Mountain, A
    Flowers, DA
    Bernstein, I
    [J]. BIOCONJUGATE CHEMISTRY, 2002, 13 (01) : 47 - 58
  • [12] Scaffolds for blocking protein-protein interactions
    Hershberger, Stefan J.
    Lee, Song-Gil
    Chmielewski, Jean
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (10) : 928 - 942
  • [13] HALICHONDRINS - ANTITUMOR POLYETHER MACROLIDES FROM A MARINE SPONGE
    HIRATA, Y
    UEMURA, D
    [J]. PURE AND APPLIED CHEMISTRY, 1986, 58 (05) : 701 - 710
  • [14] Network pharmacology: the next paradigm in drug discovery
    Hopkins, Andrew L.
    [J]. NATURE CHEMICAL BIOLOGY, 2008, 4 (11) : 682 - 690
  • [15] Polyketide synthase chemistry does not direct biosynthetic divergence between 9-and 10-membered enediynes
    Horsman, Geoff P.
    Chen, Yihua
    Thorson, Jon S.
    Shen, Ben
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (25) : 11331 - 11335
  • [16] Huyck TK, 2011, NAT REV DRUG DISCOV, V10, P173, DOI 10.1038/nrd3389
  • [17] Can the pharmaceutical industry reduce attrition rates?
    Kola, I
    Landis, J
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 711 - 715
  • [18] Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens
    Laureti, Luisa
    Song, Lijiang
    Huang, Sheng
    Corre, Christophe
    Leblond, Pierre
    Challis, Gregory L.
    Aigle, Bertrand
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (15) : 6258 - 6263
  • [19] CALCINEURIN IS A COMMON TARGET OF CYCLOPHILIN-CYCLOSPORINE-A AND FKBP-FK506 COMPLEXES
    LIU, J
    FARMER, JD
    LANE, WS
    FRIEDMAN, J
    WEISSMAN, I
    SCHREIBER, SL
    [J]. CELL, 1991, 66 (04) : 807 - 815
  • [20] Designed multiple ligands. An emerging drug discovery paradigm
    Morphy, R
    Rankovic, Z
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (21) : 6523 - 6543
1234